Skip to main content

Select Drug Profiles

Payers' Guide, FDA Approvals

Defitelio (Defibrotide Sodium): First Drug Approved for Patients with Hepatic Veno-Occlusive Disease

Payers' Guide, FDA Approvals

Gazyva (Obinutuzumab) Approved for Patients with Rituximab-Refractory Follicular Lymphoma

Payers' Guide, FDA Approvals

Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma

Payers' Guide, FDA Approvals

Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes

Payers' Guide, FDA Approvals

Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Innovation Continues to Drive Drug Development, Even as FDA Approvals Drop in 2016

Dalia Buffery, MA, ABD

Page 94 of 244
Results 931 - 940 of 2438